Oncology
Intersect on FHIR™ delivers a complete molecular tumor board workflow — hereditary cancer genomics, pharmacogenomics-informed treatment, remote patient monitoring, and CIViC-annotated variant-to-therapy matching — live today on a single FHIR R6-native platform built to CodeX mCODE standards.
Where We Are
The molecular tumor board is no longer on the roadmap — it is operational. Five genomic panels, CIViC variant annotation, and individual FDA agent matching are live in the platform today.
Hereditary Cancer Panels
Hereditary cancer risk identification is where genomics has its clearest near-term clinical impact. All panels are fully realized clinical views integrated with the complete patient record.
BRCA1, BRCA2, and related hereditary cancer syndrome variants — the most clinically actionable hereditary cancer risk panel.
Mismatch repair gene variants causing Lynch Syndrome — the most common hereditary colorectal cancer syndrome, affecting 1 in 279 Americans.
Molecular Tumor Board · Operational
Molecular tumor boards are standard of care in academic oncology — but the data infrastructure to run them efficiently has not existed at most institutions. Intersect on FHIR™ delivers that infrastructure on CodeX mCODE standards, fully operational today.
Oncologist submits a patient case directly from the Intersect clinical record — genomic variants, pathology, imaging, and treatment history pre-populated from FHIR resources. No duplicate data entry.
Variants are automatically enriched against the CIViC clinical evidence database — returning pathogenicity, evidence level, and associated disease and therapy data in structured FHIR format.
FDA DailyMed labels are retrieved for individual agents — not drug classes. Erlotinib, gefitinib, and osimertinib are evaluated separately, not grouped as "EGFR inhibitors." This is the standard the CodeX GenomicX workgroup is building toward.
Oncologist, pathologist, genetic counselor, and radiologist review structured genomic data in a shared view — built to CodeX mCODE standards for interoperability across any participating system.
Recommendations are documented as structured FHIR resources — not free text — and flow into the patient's longitudinal record, informing subsequent treatment decisions and clinical alerts for every provider.
Current practice matches genomic variants to drug classes. Intersect matches to individual agents using FDA DailyMed labels — distinguishing erlotinib from gefitinib from osimertinib for a specific EGFR variant. This distinction is clinically significant and operationally live today.
The minimal Common Oncology Data Elements (mCODE) framework defines how structured cancer data should be represented in FHIR. Intersect implements mCODE as an active CodeX GenomicX member — building to the standard as it is written, not adapting to it after the fact.
The workflow is live. We are now seeking an academic oncology program to co-develop real-world evidence, publish outcomes, and shape how CodeX standards are applied in a production environment. Early partners have first access to new capabilities at launch.
Pharmacogenomics in Oncology
Oncology pharmacogenomics is among the highest-stakes applications of gene-drug interaction knowledge. Intersect surfaces relevant pharmacogenomic findings at the point of prescribing — before the order is placed.
DPYD deficiency causes severe, potentially fatal toxicity from 5-FU — a widely used chemotherapy. Intersect generates a clinical alert before the order is placed for any patient with a relevant DPYD variant on file.
BRCA1/2 pathogenic variants flag patients as potentially eligible for PARP inhibitor therapy — a targeted treatment class that requires genomic confirmation. The flag appears in the clinical record at the point of treatment planning.
Pharmacogenomic findings are not siloed in the oncology department. Any prescriber — hospitalist, palliative care, primary care — who orders a medication for this patient sees the relevant genomic context.
Remote Patient Monitoring
Cancer treatment creates ongoing monitoring needs between clinical visits — weight loss, fatigue, fever, symptom burden. Intersect RPM keeps the care team connected to the patient throughout the treatment course.
Continuous vital monitoring during active treatment — alerting the care team to signs of toxicity, infection, or deterioration before they become emergencies.
For patients in active surveillance or on maintenance therapy, RPM extends clinical oversight beyond the walls of the cancer center.
Video visits built into the same platform as RPM and genomics — so the genetic counselor and oncologist see the same complete record during every virtual visit.
Cancer patients navigating complex treatment plans need clear, accessible information. The Intersect app puts the right guidance in their hands.
The molecular tumor board workflow is live. We are seeking an academic oncology program to generate real-world evidence alongside us — joint development, shared outcomes data, and a publication opportunity. If your program is ready to move precision oncology infrastructure forward, let's talk.
See how Intersect on FHIR™ connects hereditary cancer genomics, pharmacogenomics, a live molecular tumor board, and remote monitoring into a complete oncology care model.
Request a Demo